AGP Picks
View all

LATAM Technology Reporter
Provided by AGP

LATAM Technology Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Technology Reporter.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on August 10, 2026

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
Aug. 10, 2026

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

Indeterminate GlobeNewswire
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
Aug. 10, 2026

Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia

Indeterminate GlobeNewswire
Bitdeer Reports Unaudited Financial Results for the Second Quarter of 2026
Aug. 10, 2026

Bitdeer Reports Unaudited Financial Results for the Second Quarter of 2026

Indeterminate GlobeNewswire
Kaspi.kz 2Q & 1H 2026 Financial Results
Aug. 10, 2026

Kaspi.kz 2Q & 1H 2026 Financial Results

Indeterminate GlobeNewswire
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
Aug. 10, 2026

Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology

Indeterminate GlobeNewswire
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Aug. 10, 2026

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

Indeterminate GlobeNewswire
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Aug. 10, 2026

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Indeterminate GlobeNewswire
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug. 10, 2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Indeterminate GlobeNewswire
Aeries Technology Reports Strong Results for April - June 2026 Quarter
Aug. 10, 2026

Aeries Technology Reports Strong Results for April - June 2026 Quarter

Indeterminate GlobeNewswire
Goliath Reports Up To 9.87 G/T Au Over 5.00 Meters, Confirms A 320 Meter Expansion Of Golden Gate Zone to The Northeast, Remains Open, On High-Grade Gold Surebet Discovery, Golden Triangle, B.C.
Aug. 10, 2026

Goliath Reports Up To 9.87 G/T Au Over 5.00 Meters, Confirms A 320 Meter Expansion Of Golden Gate Zone to The Northeast, Remains Open, On High-Grade Gold Surebet Discovery, Golden Triangle, B.C.

Indeterminate GlobeNewswire
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Aug. 10, 2026

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Indeterminate GlobeNewswire
Red Cat Announces Multiyear Partnership with Washington Commanders to Support America's Military Community
Aug. 10, 2026

Red Cat Announces Multiyear Partnership with Washington Commanders to Support America's Military Community

Indeterminate GlobeNewswire
Hopstem Announces the first Closing of Series C Financing to Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy
Aug. 10, 2026

Hopstem Announces the first Closing of Series C Financing to Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy

Indeterminate GlobeNewswire
Huize Holding Limited to Report First Half 2026 Financial Results on August 20, 2026
Aug. 10, 2026

Huize Holding Limited to Report First Half 2026 Financial Results on August 20, 2026

Indeterminate GlobeNewswire
TAIONE Open Source Foundation and Embedded LLM Collaborate to Build Taiwan's vLLM Ecosystem
Aug. 10, 2026

TAIONE Open Source Foundation and Embedded LLM Collaborate to Build Taiwan's vLLM Ecosystem

Indeterminate GlobeNewswire
Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development
Aug. 10, 2026

Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development

Indeterminate GlobeNewswire
Percona Live Amsterdam bringt die Open-Source-Community zusammen und richtet den Blick auf die Zukunft von Open-Source-Datenbanken
Aug. 10, 2026

Percona Live Amsterdam bringt die Open-Source-Community zusammen und richtet den Blick auf die Zukunft von Open-Source-Datenbanken

Indeterminate GlobeNewswire
Percona Live Amsterdam réunit la communauté autour de l’avenir des bases de données open source
Aug. 10, 2026

Percona Live Amsterdam réunit la communauté autour de l’avenir des bases de données open source

Indeterminate GlobeNewswire
Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security
Aug. 10, 2026

Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security

Indeterminate GlobeNewswire
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Aug. 10, 2026

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM Technology Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.